

Worked Example:

Fast Follower: Optimising P450 Metabolic Stability

In this example, we will explore the feasibility of pursuing a fast-follower for Buspirone, a 5- HT_{1A} ligand used as an anti-anxiolytic therapeutic. Buspirone has a known liability due to rapid metabolism by CYP3A4, leading to low oral bioavailability and a short half-life in man. The project wished to efficiently identify analogues of Buspirone with an *in vitro* CYP3A4 half-life 3-times longer than Buspirone and a minimum loss of receptor affinity.

The structure of Buspirone can be broken down into three regions:



Arylpiperazine

- Protonatable recognition element, receptor affinity
- Metabolism: Hydroxylation at pyrimidine C5

Tetramethylene linker

Metabolism: Ndealkylation α to piperazine N4



Piperidinedione moiety

Metabolism: oxidation of spirocyclopentane ring

Our objective is to identify structural modifications that reduce the vulnerability of key sites of metabolism, as indicated by decreasing the **site lability**, and identify molecules that are likely to meet the project goal of increased half-life with respect to metabolism by CYP3A4 by reducing the **composite site lability** (CSL).



Optibrium[™], Nova[™], StarDrop[™], Card View[®], Glowing Molecule[™], WhichP450[™] and Auto-Modeller[™] are trademarks of Optibrium Ltd. © 2022 Optibrium Ltd. We will investigate modifications to the different regions of Buspirone identified above using two different series: Series 1 will explore alternative aryl substitutions on the piperazine; Series 2 will explore modifications to the tetramethylene linker and piperidinedione moiety. Finally, we will explore the impact of combinations of the most promising modifications.

Exercise

 In StarDrop, open the StarDrop project file Buspirone.sdproj by selecting Open from File menu.

👯 Select file(s) to op	en					×		
\leftarrow \rightarrow \checkmark \uparrow \square \Rightarrow This PC \Rightarrow Documents \Rightarrow StarDrop Example \checkmark \circlearrowright					Search StarDrop Example 🛛 🔎			
Organize 👻 Ne	w folder				8== -			
A Quick second	^	Name	^	Date mounea	Siz	ze		
		🗹 🐛 Buspirone		21/05/2018 09:57	StarDrop Project	59 KB		
👽 Dropbox								
i OneDrive 🍊								
SharePoint								
💻 This PC								
3D Objects	~							
	File <u>n</u> ame:	Buspirone		~	Supported Files(*.sdpro	oj *.add * 🗸		
					<u>O</u> pen	Cancel		

 The first data set displayed, BuspironeS1, contains 9 compounds, the first of which is Buspirone. For each compound, its structure, identifier, and experimental measurements of half-life with respect to metabolism by CYP3A4 and IC₅₀ against 5HT_{1A} are shown.



• Change to the P450 area, select the first compound in the table, Buspirone, and



submit this compound to the P450 models by clicking on the 🖻 button.

When the calculations are complete, the results will be returned from the server, with a summary displayed in the table and in the P450 area (**Hint:** the regions of the P450 area can be resized to enlarge the regioselectivity, WhichP450[™] and site lability views). The calculation will take roughly 1-2 minutes for a compound; however, if the results for a compound have previously been calculated on your server, the results will be returned instantly.



The result from the WhichP450 model, shown by the pie chart, indicates that Buspirone is most likely to be metabolised by CYP3A4, in agreement with its known primary route of metabolism.



Above this is a summary of the predicted regioselectivity of metabolism by the major isoforms predicted to contribute significantly, in this case only CYP3A4.

• Click on the **3A4** tab within the P450 area to focus on the predicted metabolism by this isoform.

🛠 StarDrop - Buspirone							- 0	×
File Edit View Data Set Tools Custom Scripts Help	6 Q	P450 Isoform	P450	Structure	ID	CYP3A4 T1/2 (min)	5HT1A IC	
Summary 3A4 2D6 2C9 2C8 2C19 2E1 1A2	1	344	0.951		buspirone	4.6	c	ବ୍ <u>ଚ</u>
	C23.C24:3%	Not Calculated	Uncalculated	- 00 } x	buspAPpyrim5F	52.3	c	1
	3	Not Calculated	Uncalculated	- 0-0- } X	buspAPphen4F	3.2	c	
C9,C11: 4% C8,C12: 2%	4	Not Calculated	Uncalculated		buspAPpyrid2	4.7	c	
3A4 Metabolic Landscape CSL = 0.9506	Labile Mod Labile Mod Stable	Not Calculated	Uncalculated	0-0}x	buspAPpyraz2	5.5		Jac
H	Unknown 6	Not Calculated	Uncalculated	,00,-,) X	buspAPphen40Me	21.1		
CT CT3 C9 CT1 C24 C23 C8 CT2 N5 N3 C25 C22 N7 CT6 C26 C20 CT4 N17 C6 C2 CT5		Not Calculated	Uncalculated	- 2-0-0- 2-] buspAPphen30Me	3.3	c	RI
1 C1 56 Jabile		Not Calculated	Uncalculated	<u>2017</u> x	buspAPphen20Me	5.1	c	
	۹ ۱۹	Not Calculated	Uncalculated		buspAPphenyl	8	c	
2 C13 32 Labile								
🐁 🔹 🐌 Server Status: No molecules in queue	⇒		ca 37	Pure' C	3.ª	Cambi - 1	>	
leady	*	 Buspirone 	201 Xe	BuspironeS2 Row	9 (0) Columns 6 (0) Select	ed 1 Server status: 🔾 🔾	0000	5

Here we can see good agreement between the predictions from the model and the known metabolism of Buspirone by CYP3A4. The predominant sites of metabolism are predicted to be at the para position of the pyrimidine (C1) and the carbon in the tetramethylene linker α to the piperazine nitrogen (C13).

The **Metabolic Landscape** indicates the lability of each site with respect to metabolism by CYP3A4 in absolute terms to guide the optimisation of compounds with improved metabolic stability.



This indicates that, although the proportion of metabolism on the spirocyclopentane moiety (C23, C24) is predicted to be small, this is predicted to be a moderately labile site, again in agreement with the observation of metabolism at this position. C9 and C11 on the piperazine are also predicted to be moderately labile, although these are not observed experimentally.

The **CSL** (composite site lability) is shown in the top-left of the metabolic landscape, as well as in the **P450** column in the data set. This is a measure of the efficiency of the product formation step in the catalytic cycle of CYP3A4. Thus, a lower CSL value indicates a greater likelihood of improved stability.

We will now explore the impact of potential modifications on the predicted lability at each observed site of metabolism. The **BuspironeS1** data set explores alternative aryl substitutions on the piperazine.

 Click on the top-left corner of the table below the Q button to select all the rows in the data set and submit these to the P450 models by clicking on the button.



- Selecting a row in the spreadsheet will display the detailed results in the P450 area.
- Examine each of the compounds, in turn, to identify modifications to the aryl group that improve the vulnerability of this region of the molecule to metabolism by CYP3A4. This will be indicated by lower **site lability** bars shown for the corresponding



sites in the **Metabolic Landscape** view. An example of such a modification is shown here:

The experimental data indicate that this change alone results in an improvement in half-life by a factor of 10 while maintaining an IC_{50} of approximately 60 nM.

The CSL for many of the compounds remains high because, in this case, we are modifying only one region of the molecule, but other labile sites remain; therefore, there may be only a small change in the overall CSL, even for a beneficial modification. Also, other factors influence the overall rate of metabolism (in particular logP and pK_a); therefore, we do not necessarily expect a direct correlation between the small changes to CSL and the CYP3A4 half-life at this stage.

- Change to the **BuspironeS2** data set by clicking on the corresponding tab at the bottom of the data set. This contains the compounds in Series 2 that explore modifications to the tetramethylene linker and piperidinedione moiety.
- Run the P450 calculations for Series 2, as described above for Series 1, and explore the results, paying particular attention to changes that reduce the site labilities on the tetramethylene linker and piperidinedione moiety.

K StarDrop - Buspirone File Edit View Data Set Tools Custom Scripts Help								- 0	×
6	🔍 📕 P450 Iso	form	P450		Structure	ID	CYP3A4 T1/2 (min)	SHT1A IC	
Visualisation Models Scoring Design SeeSAR 3D P450 Nova Auto P Summary 3A4 2D6 2C9 2C8 2C19 2E1 1A2	1	3A4		0.951		buspirone	4.6	c	∞ ▲
	2	3A4		0.942	\$ OK yo	buspLSalmet	3.8	c	111 111
	3	3A4		0.927	Stripo	buspLSbdimet	2.9		₹ <u>₽</u>
Ch: 1%, N224, N226; 1% Ch: 21%	4	3A4		0.942	r fr	buspLSaloh	10.2		₩ ₩
3A4 Metabolic Landscape CSL = 0.9461 Mod Labile Mod Stable Stable	5	3A4		0.933	ad the	buspLSbohmet	8.5		Joo
Unknown	6	3A4		0.946	0.0172	buspLSgemdimet	30.5	c	**
C26 C2 C12 C11 C22 C18 N28 N24 C21 C19 C1 N20 C5 N6 C4 C3 C27 C25 C13 C10 Site Ratio % Lability Metabolites ^	7	3A4		0.938	47.00	buspLSamegemdimet			RI Q
1 C25 62 Labile	8	3A4		0.953		buspLSphthal	26.8		
	•	3A4		0.946	\$~~~	buspLSamephthal	15.4	c	
2 C2 21 Mod Labile									
🚳 👻 💘 Server Status: No molecules in queue								>	
Ready		Buspiror	1651	*	BuspironeS2 Rows	9 (0, 5 6 (0) Selecte	Combined d 9 Server status: 🥥 🔾		•
L									

An example result is shown below:



This indicates that replacing the spiropentane with a dimethyl substitution removes two moderately labile sites. Perhaps surprisingly, given the remaining presence of two highly labile

sites on this compound, this modification is sufficient to improve the half-life from 4.6 minutes to 30.5 minutes.

Finally, we would like to explore combinations of the modifications we have identified to find compounds with improved overall stability while avoiding those changes that caused a large decrease in potency.

• Change to the **Combined** data set to run the P450 models on these three examples, as described previously.



Note that all of these compounds have significantly better (lower) CSL values than Buspirone and meet the objective of greater than 3-times the half-life of Buspirone. Furthermore, in two cases, IC_{50} values against 5-HT_{1A} of less than 0.1 μ M have been retained.

• You can explore further modifications by drawing new molecules in the **Design** area.

Add these to the dataset using the button before switching to the **P450** area and submitting the molecules to the P450 models.



Further details of the chemistry, assays and results in this study can be found in Tandon et al. The design and preparation of metabolically protected new aryl-piperazine 5-HT1A ligands. Bioorg. Med. Chem. Lett. 2004 14(7) pp. 1709-12. If you have any questions, please feel free to contact <u>stardrop-support@optibrium.com</u>.